494 related articles for article (PubMed ID: 30810330)
1. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
[TBL] [Abstract][Full Text] [Related]
2. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.
Petta S; Cammà C; Cabibi D; Di Marco V; Craxì A
Aliment Pharmacol Ther; 2011 Oct; 34(7):757-66. PubMed ID: 21790685
[TBL] [Abstract][Full Text] [Related]
3. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
4. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults.
Zheng X; Gong L; Luo R; Chen H; Peng B; Ren W; Wang Y
Lipids Health Dis; 2017 Oct; 16(1):202. PubMed ID: 29037239
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.
Liu PJ; Ma F; Lou HP; Zhu YN; Chen Y
Climacteric; 2014 Dec; 17(6):692-9. PubMed ID: 24884478
[TBL] [Abstract][Full Text] [Related]
6. The relationship of serum uric acid with non-alcoholic fatty liver disease.
Sertoglu E; Ercin CN; Celebi G; Gurel H; Kayadibi H; Genc H; Kara M; Dogru T
Clin Biochem; 2014 Apr; 47(6):383-8. PubMed ID: 24525254
[TBL] [Abstract][Full Text] [Related]
7. Higher Serum Uric Acid Level Predicts Non-alcoholic Fatty Liver Disease: A 4-Year Prospective Cohort Study.
Wei F; Li J; Chen C; Zhang K; Cao L; Wang X; Ma J; Feng S; Li WD
Front Endocrinol (Lausanne); 2020; 11():179. PubMed ID: 32328031
[No Abstract] [Full Text] [Related]
8. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.
Sirota JC; McFann K; Targher G; Johnson RJ; Chonchol M; Jalal DI
Metabolism; 2013 Mar; 62(3):392-9. PubMed ID: 23036645
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients.
Huang JF; Yeh ML; Yu ML; Huang CF; Dai CY; Hsieh MY; Hsieh MH; Huang CI; Lin ZY; Chen SC; Hsiao PJ; Shin SJ; Chuang WL
PLoS One; 2015; 10(10):e0139796. PubMed ID: 26441244
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients.
Oral A; Sahin T; Turker F; Kocak E
Medicina (Kaunas); 2019 Sep; 55(9):. PubMed ID: 31533345
[No Abstract] [Full Text] [Related]
12. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Jaruvongvanich V; Ahuja W; Wirunsawanya K; Wijarnpreecha K; Ungprasert P
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1031-1035. PubMed ID: 28639970
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
14. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
15. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
Mosca A; Nobili V; De Vito R; Crudele A; Scorletti E; Villani A; Alisi A; Byrne CD
J Hepatol; 2017 May; 66(5):1031-1036. PubMed ID: 28214020
[TBL] [Abstract][Full Text] [Related]
16. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE;
Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442
[TBL] [Abstract][Full Text] [Related]
17. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents.
Cardoso AS; Gonzaga NC; Medeiros CC; Carvalho DF
J Pediatr (Rio J); 2013; 89(4):412-8. PubMed ID: 23791233
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between serum uric acid and risk of new-onset nonalcoholic fatty liver disease: a 5-year observational cohort study].
Bai JX; Shu RM; Huang Y; Peng Z
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):271-275. PubMed ID: 29996338
[No Abstract] [Full Text] [Related]
19. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease.
Zhou M; Yang N; Xing X; Chang D; Li J; Deng J; Chen Y; Hu C; Zhang R; Lu X; Zhao Y; He Y
BMC Gastroenterol; 2021 Jan; 21(1):43. PubMed ID: 33509116
[TBL] [Abstract][Full Text] [Related]
20. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
